On January 8, Zenas BioPharma chief executive Leon Moulder, Jr. executed a direct purchase of 30,000 company shares, representing a 9.49% increase in his personal holding. The transaction, disclosed via SEC Form 4, amounted to $489,000 and raised his total share ownership to 346,155. This insider acquisition marks the third consecutive day of buying activity by Moulder, Jr., who has committed approximately $1.63 million to expand his stake over January 7–9, signaling strong management confidence in the company’s mid-term prospects.

Zenas BioPharma reported a fourth-quarter EPS loss of $1.22, missing consensus estimates by $0.35, as disclosed in its November 12 earnings release. The balance sheet shows a quick ratio and current ratio both at 5.66, and a debt-to-equity ratio of 0.37, reflecting a conservative leverage profile. Institutional investors have ramped up positions—Federated Hermes raised its stake by 60.8%, Vanguard by 17.2%—underscoring growing institutional conviction. On the sell-side, six analysts maintain buy or outperform views, one holds, and one recommends sell; the consensus price target stands at $43.14, indicating meaningful upside from current levels as per MarketBeat aggregation.